Former Verily execs launch effort to transform clinical trials
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Two former top Verily execs have started a company that aims to improve clinical trials by advancing new...
View ArticleClik here to view.
Innovent Biologics highlights subgroup of lung cancer patients in early-stage...
Innovent Biologics reported Monday that 20.8% of advanced lung cancer patients saw their tumors shrink at least 30% after receiving an experimental bispecific antibody that’s meant to boost T cell...
View ArticleClik here to view.
Sanofi opens ‘world first’ modular vaccines and biologics factory in France
Sanofi has completed construction of a so-called modular facility in France that the company said can quickly switch manufacturing processes that would traditionally take months to complete. The...
View ArticleXencor’s $175M offering; Viridian to raise $150M
Plus, news about Hyundai Bioscience, Clear Scientific and Terns Pharmaceuticals: Xencor prices $175M offering: The Pasadena, CA-based biotech made the financing move after announcing drug candidates in...
View ArticleClik here to view.
Roche says its Carmot-acquired obesity pill is effective in early study
Roche’s once-daily oral weight loss pill helped Phase 1 subjects lose up to 7.3% of their body weight within one month, which is less than competitors who measured the performance of their oral options...
View ArticleFDA drafts new strategy to boost the use of advanced manufacturing tech
The FDA on Wednesday unveiled the outline of its plans to support the use of new drug manufacturing technologies, part of the agency’s commitments under the latest user fee program. The seven-page...
View ArticleClik here to view.
Novo Nordisk's longstanding GLP-1 reduced BMI by 7% in children in Phase 3 trial
Novo Nordisk said children between the ages of 6 and 12 saw a 7.4% reduction in BMI over about a year in a late-stage trial investigating its weight loss drug Saxenda in a pediatric population. The...
View ArticleCVS says it won't correct congressional testimony
The head of CVS Health’s PBM unit won’t correct testimony given to Congress, the company’s lawyers said in a letter to the House Oversight Committee, arguing that the executive’s comments were...
View ArticleClik here to view.
J&J expands Tremfya into IBD with new FDA approval
The FDA has approved Johnson & Johnson’s IL-23 blocker Tremfya to treat ulcerative colitis, a boost to the pharma’s hopes that the drug will serve as a worthy follow-up to the blockbuster Stelara....
View ArticleClik here to view.
Sanofi buys into radiopharmaceutical field with $110M upfront, going after...
While it’s put more emphasis on becoming an “immunology powerhouse” in recent quarters, Sanofi still shows signs of interest in oncology. On Thursday it announced licensing deals with the radiopharma...
View ArticleModerna plans $1.1B in R&D and program cuts, delays break-even point to 2028
Stéphane Bancel has relented to Wall Street’s desire for cost-cutting and reining in Moderna’s pipeline. To kick off its annual R&D day in New York, Moderna said Thursday that it will slash its...
View ArticleAura's infrared light-activated drug stops tumor growth and preserves vision...
Aura Biosciences said eight of 10 patients with a rare eye cancer who received a therapeutic dose of its experimental virus-like drug conjugate saw their tumors stop growing at one year. Of the 10...
View ArticleClik here to view.
F2G inks $100M Series H for another shot at treating fungal infections
Manchester, UK-based F2G has patched together another $100 million in funding a little over a year after receiving a CRL for its experimental fungal infection drug known as olorofim, it said Thursday...
View ArticleClik here to view.
Cancer gene therapy startup Vironexis emerges from stealth with $26M seed round
A new startup attempting to develop AAV gene therapies to treat cancer emerged from stealth Thursday morning with $26 million in seed funding — and a plan to quickly get into the clinic. Vironexis...
View ArticleClik here to view.
Noom offers compounded GLP-1 drugs, promises patients can quit and keep...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Noom is the latest weight loss startup to start prescribing compounded versions of the obesity...
View ArticleGilead says twice-yearly HIV prevention shot succeeds in second pivotal trial
Gilead announced that its twice-a-year HIV injection prevented all but two cases of HIV among 2,180 participants in a Phase 3 study as it prepares to launch the drug, called lenacapavir, in 2025 for...
View ArticleLilly budgets $1.8B to boost Kisunla, GLP-1 manufacturing in Ireland
Eli Lilly is rapidly increasing its presence in Ireland with a $1 billion expansion to bolster its biologic drug production and a separate $800 million investment to further grow its GLP-1...
View ArticleSofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near...
In what’s shaping up to be another slow year for biotech IPOs — better, however, than the 2022 and 2023 doldrums — Jim Healy is somewhat of an outlier. Only four biotechs from this year’s IPO class are...
View ArticleCharles River to lay off 3% of staffers as it streamlines spending
Charles River Laboratories is cutting around 3% of its total workforce in “response to current trends,” a company spokesperson told Endpoints News in an email. The Wilmington, MA-based company is...
View ArticleFulcrum's Phase 3 for old GSK drug fails, stock sinks
Fulcrum Therapeutics reported a Phase 3 fail Thursday morning, sending its stock plummeting. The biotech said that a study testing the former GSK cardio drug losmapimod in facioscapulohumeral muscular...
View Article